SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
VaccinesCancer

PUBLISHER: Fairfield Market Research | PRODUCT CODE: 2169354

Cover Image

PUBLISHER: Fairfield Market Research | PRODUCT CODE: 2169354

Personalized Cancer Vaccine Market Insights, Competitive Landscape, and Market Forecast - 2033

PUBLISHED:
PAGES: 280 Pages
DELIVERY TIME: 2-5 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
Unprintable PDF & Excel (Single User License)
USD 4995
Unprintable PDF & Excel (Multi User License upto 5 users)
USD 7295
Printable PDF & Excel (Enterprise License above 5 users)
USD 8495

Add to Cart

Description

Table of Contents

Introduction

Personalized cancer vaccines train a patient's own immune system to recognize the specific mutations found in that patient's tumor. Developers sequence tumor and healthy tissue, identify the neoantigens most likely to trigger a response, and then manufacture a vaccine made for one individual. This approach is moving from experimental science toward routine oncology care. In 2026, the market is valued at US$4.99 Bn and is projected to reach US$16.57 Bn by 2033, registering a CAGR of 18.70%. Momentum comes from late-stage clinical success with mRNA neoantigen vaccines, especially when combined with checkpoint inhibitors, and from the falling cost of sequencing alongside better computational prediction of which mutations matter. The market is approaching a turning point as developers complete Phase 3 studies and prepare for the first regulatory approvals of individualized neoantigen therapy in melanoma and lung cancer. Manufacturing scale, turnaround time and payer acceptance will decide how quickly these products move from specialist centers into broader clinical practice.

Market Insights

The market is segmented by vaccine type, cancer type and treatment setting. Vaccine types include neoantigen-based products, dendritic cell vaccines, tumor cell vaccines and viral vector-based vaccines, each using a different method to present tumor targets to the immune system. Cancer types covered are melanoma, lung cancer, breast cancer, prostate cancer, colorectal cancer and others. Treatment settings are divided into adjuvant use, where the vaccine is given after surgery to reduce the risk of recurrence, and metastatic use, where it targets advanced disease. The defining trend is the shift from research toward first regulatory approvals of individualized neoantigen therapy, with melanoma and lung cancer leading the way. Developers are completing Phase 3 trials, investing in individualized manufacturing that can produce a unique product for each patient on a tight schedule, and extending programs into more common cancers. This progression is turning a scientific concept into a commercial category, with sequencing, bioinformatics and production capacity becoming as important as the vaccine design itself.

Drivers

The strongest driver is late-stage clinical success of mRNA neoantigen vaccines, a high-impact factor over the medium term. Positive results in melanoma and other tumors have shown that individualized vaccines can reduce recurrence when used with existing immunotherapies, giving clinicians, investors and regulators greater confidence in the approach. A second high-impact driver, operating over the long term, is the falling cost of sequencing combined with AI-based neoantigen prediction. Cheaper tumor sequencing makes it practical to profile every patient, while better algorithms improve the selection of targets that are most likely to provoke a strong immune response. Together these factors shorten design time and raise the chance of clinical benefit. Restraints remain significant. High manufacturing costs and complex logistics carry high impact in the medium term, since each vaccine is produced for a single patient and must move quickly from biopsy to injection. Mixed clinical results and regulatory uncertainty add a medium-impact, short-term challenge as authorities define standards for products that differ for every patient.

Business Opportunity

Expansion into lung cancer and other common cancers forms the largest revenue pool ahead. Melanoma has served as the proving ground, but far more patients are diagnosed with lung, breast, colorectal and prostate cancers each year. Demonstrating benefit in these high-incidence tumors, particularly in the adjuvant setting where the goal is to prevent recurrence after surgery, would multiply the number of eligible patients and transform the commercial scale of the category. A second opportunity sits in the supporting infrastructure. Manufacturing, sequencing and AI services form a platform revenue pool for contract manufacturers and software providers. Every individualized vaccine requires tumor sequencing, computational target selection, rapid custom production and tightly controlled cold chain delivery. Companies that can offer reliable, fast and scalable versions of these services can partner with many vaccine developers at once, earning recurring revenue regardless of which individual product succeeds. Providers that reduce turnaround time and cost per patient will be especially valuable as volumes rise after the first approvals.

Region Analysis

North America leads the market with a 42.0% share in 2026, supported by a dense network of cancer centers, heavy investment in mRNA and immuno-oncology research, active clinical trial programs and a regulatory system that is actively engaging with individualized therapies. Europe is a major market as well, with strong academic research, established biotech developers and large cancer trial networks contributing to clinical progress and future adoption. Asia Pacific is the fastest-growing region, expanding at a 21.2% CAGR through 2033, as investment in biotechnology rises, sequencing capacity grows and more countries participate in global oncology trials. Rising cancer incidence and improving access to advanced treatment add to the region's momentum. Latin America represents a smaller share, where adoption is expected to follow trial participation and the development of specialist oncology centers in major cities. The Middle East and Africa is at an early stage, with demand concentrated in leading hospitals that are building capabilities in precision oncology and advanced immunotherapy.

Key Players

  • Moderna
  • Merck & Co.
  • BioNTech
  • Genentech (Roche)
  • Dendreon
  • CureVac
  • Transgene
  • Evaxion Biotech
  • Nouscom
  • OSE Immunotherapeutics

Segmentation

By Vaccine Type:

  • Neoantigen-based
  • Dendritic Cell
  • Tumor Cell
  • Viral Vector-based

By Cancer Type:

  • Melanoma
  • Lung Cancer
  • Breast Cancer
  • Prostate Cancer
  • Colorectal Cancer
  • Others

By Treatment Setting:

  • Adjuvant
  • Metastatic

By Geographic Coverage:

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa
Show more

Table of Contents

1. Executive Summary

  • 1.1. Global Personalized Cancer Vaccine Market Snapshot
  • 1.2. Future Projections
  • 1.3. Key Market Trends
  • 1.4. Regional Snapshot, by Value, 2026
  • 1.5. Analyst Recommendations

2. Market Overview

  • 2.1. Market Definitions and Segmentations
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Market Opportunities
  • 2.3. Value Chain Analysis
  • 2.4. COVID-19 Impact Analysis
  • 2.5. Porter's Five Forces Analysis
  • 2.6. Impact of Russia-Ukraine Conflict
  • 2.7. PESTLE Analysis
  • 2.8. Regulatory Analysis
  • 2.9. Price Trend Analysis
    • 2.9.1. Current Prices and Future Projections, 2025-2033
    • 2.9.2. Price Impact Factors

3. Global Personalized Cancer Vaccine Market Outlook, 2020 - 2033

  • 3.1. Global Personalized Cancer Vaccine Market Outlook, by Vaccine Type, Value (US$ Bn), 2020-2033
    • 3.1.1. Neoantigen-based
    • 3.1.2. Dendritic Cell
    • 3.1.3. Tumor Cell
    • 3.1.4. Viral Vector-based
  • 3.2. Global Personalized Cancer Vaccine Market Outlook, by Cancer Type, Value (US$ Bn), 2020-2033
    • 3.2.1. Melanoma
    • 3.2.2. Lung Cancer
    • 3.2.3. Breast Cancer
    • 3.2.4. Prostate Cancer
    • 3.2.5. Colorectal Cancer
    • 3.2.6. Others
  • 3.3. Global Personalized Cancer Vaccine Market Outlook, by Treatment Setting, Value (US$ Bn), 2020-2033
    • 3.3.1. Adjuvant
    • 3.3.2. Metastatic
  • 3.4. Global Personalized Cancer Vaccine Market Outlook, by Region, Value (US$ Bn), 2020-2033
    • 3.4.1. North America
    • 3.4.2. Europe
    • 3.4.3. Asia Pacific
    • 3.4.4. Latin America
    • 3.4.5. Middle East & Africa

4. North America Personalized Cancer Vaccine Market Outlook, 2020 - 2033

  • 4.1. North America Personalized Cancer Vaccine Market Outlook, by Vaccine Type, Value (US$ Bn), 2020-2033
    • 4.1.1. Neoantigen-based
    • 4.1.2. Dendritic Cell
    • 4.1.3. Tumor Cell
    • 4.1.4. Viral Vector-based
  • 4.2. North America Personalized Cancer Vaccine Market Outlook, by Cancer Type, Value (US$ Bn), 2020-2033
    • 4.2.1. Melanoma
    • 4.2.2. Lung Cancer
    • 4.2.3. Breast Cancer
    • 4.2.4. Prostate Cancer
    • 4.2.5. Colorectal Cancer
    • 4.2.6. Others
  • 4.3. North America Personalized Cancer Vaccine Market Outlook, by Treatment Setting, Value (US$ Bn), 2020-2033
    • 4.3.1. Adjuvant
    • 4.3.2. Metastatic
  • 4.4. North America Personalized Cancer Vaccine Market Outlook, by Country, Value (US$ Bn), 2020-2033
    • 4.4.1. U.S. Personalized Cancer Vaccine Market Outlook, by Vaccine Type, 2020-2033
    • 4.4.2. U.S. Personalized Cancer Vaccine Market Outlook, by Cancer Type, 2020-2033
    • 4.4.3. U.S. Personalized Cancer Vaccine Market Outlook, by Treatment Setting, 2020-2033
    • 4.4.4. Canada Personalized Cancer Vaccine Market Outlook, by Vaccine Type, 2020-2033
    • 4.4.5. Canada Personalized Cancer Vaccine Market Outlook, by Cancer Type, 2020-2033
    • 4.4.6. Canada Personalized Cancer Vaccine Market Outlook, by Treatment Setting, 2020-2033
  • 4.5. BPS Analysis/Market Attractiveness Analysis

5. Europe Personalized Cancer Vaccine Market Outlook, 2020 - 2033

  • 5.1. Europe Personalized Cancer Vaccine Market Outlook, by Vaccine Type, Value (US$ Bn), 2020-2033
    • 5.1.1. Neoantigen-based
    • 5.1.2. Dendritic Cell
    • 5.1.3. Tumor Cell
    • 5.1.4. Viral Vector-based
  • 5.2. Europe Personalized Cancer Vaccine Market Outlook, by Cancer Type, Value (US$ Bn), 2020-2033
    • 5.2.1. Melanoma
    • 5.2.2. Lung Cancer
    • 5.2.3. Breast Cancer
    • 5.2.4. Prostate Cancer
    • 5.2.5. Colorectal Cancer
    • 5.2.6. Others
  • 5.3. Europe Personalized Cancer Vaccine Market Outlook, by Treatment Setting, Value (US$ Bn), 2020-2033
    • 5.3.1. Adjuvant
    • 5.3.2. Metastatic
  • 5.4. Europe Personalized Cancer Vaccine Market Outlook, by Country, Value (US$ Bn), 2020-2033
    • 5.4.1. Germany Personalized Cancer Vaccine Market Outlook, by Vaccine Type, 2020-2033
    • 5.4.2. Germany Personalized Cancer Vaccine Market Outlook, by Cancer Type, 2020-2033
    • 5.4.3. Germany Personalized Cancer Vaccine Market Outlook, by Treatment Setting, 2020-2033
    • 5.4.4. Italy Personalized Cancer Vaccine Market Outlook, by Vaccine Type, 2020-2033
    • 5.4.5. Italy Personalized Cancer Vaccine Market Outlook, by Cancer Type, 2020-2033
    • 5.4.6. Italy Personalized Cancer Vaccine Market Outlook, by Treatment Setting, 2020-2033
    • 5.4.7. France Personalized Cancer Vaccine Market Outlook, by Vaccine Type, 2020-2033
    • 5.4.8. France Personalized Cancer Vaccine Market Outlook, by Cancer Type, 2020-2033
    • 5.4.9. France Personalized Cancer Vaccine Market Outlook, by Treatment Setting, 2020-2033
    • 5.4.10. U.K. Personalized Cancer Vaccine Market Outlook, by Vaccine Type, 2020-2033
    • 5.4.11. U.K. Personalized Cancer Vaccine Market Outlook, by Cancer Type, 2020-2033
    • 5.4.12. U.K. Personalized Cancer Vaccine Market Outlook, by Treatment Setting, 2020-2033
    • 5.4.13. Spain Personalized Cancer Vaccine Market Outlook, by Vaccine Type, 2020-2033
    • 5.4.14. Spain Personalized Cancer Vaccine Market Outlook, by Cancer Type, 2020-2033
    • 5.4.15. Spain Personalized Cancer Vaccine Market Outlook, by Treatment Setting, 2020-2033
    • 5.4.16. Russia Personalized Cancer Vaccine Market Outlook, by Vaccine Type, 2020-2033
    • 5.4.17. Russia Personalized Cancer Vaccine Market Outlook, by Cancer Type, 2020-2033
    • 5.4.18. Russia Personalized Cancer Vaccine Market Outlook, by Treatment Setting, 2020-2033
    • 5.4.19. Rest of Europe Personalized Cancer Vaccine Market Outlook, by Vaccine Type, 2020-2033
    • 5.4.20. Rest of Europe Personalized Cancer Vaccine Market Outlook, by Cancer Type, 2020-2033
    • 5.4.21. Rest of Europe Personalized Cancer Vaccine Market Outlook, by Treatment Setting, 2020-2033
  • 5.5. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Personalized Cancer Vaccine Market Outlook, 2020 - 2033

  • 6.1. Asia Pacific Personalized Cancer Vaccine Market Outlook, by Vaccine Type, Value (US$ Bn), 2020-2033
    • 6.1.1. Neoantigen-based
    • 6.1.2. Dendritic Cell
    • 6.1.3. Tumor Cell
    • 6.1.4. Viral Vector-based
  • 6.2. Asia Pacific Personalized Cancer Vaccine Market Outlook, by Cancer Type, Value (US$ Bn), 2020-2033
    • 6.2.1. Melanoma
    • 6.2.2. Lung Cancer
    • 6.2.3. Breast Cancer
    • 6.2.4. Prostate Cancer
    • 6.2.5. Colorectal Cancer
    • 6.2.6. Others
  • 6.3. Asia Pacific Personalized Cancer Vaccine Market Outlook, by Treatment Setting, Value (US$ Bn), 2020-2033
    • 6.3.1. Adjuvant
    • 6.3.2. Metastatic
  • 6.4. Asia Pacific Personalized Cancer Vaccine Market Outlook, by Country, Value (US$ Bn), 2020-2033
    • 6.4.1. China Personalized Cancer Vaccine Market Outlook, by Vaccine Type, 2020-2033
    • 6.4.2. China Personalized Cancer Vaccine Market Outlook, by Cancer Type, 2020-2033
    • 6.4.3. China Personalized Cancer Vaccine Market Outlook, by Treatment Setting, 2020-2033
    • 6.4.4. Japan Personalized Cancer Vaccine Market Outlook, by Vaccine Type, 2020-2033
    • 6.4.5. Japan Personalized Cancer Vaccine Market Outlook, by Cancer Type, 2020-2033
    • 6.4.6. Japan Personalized Cancer Vaccine Market Outlook, by Treatment Setting, 2020-2033
    • 6.4.7. South Korea Personalized Cancer Vaccine Market Outlook, by Vaccine Type, 2020-2033
    • 6.4.8. South Korea Personalized Cancer Vaccine Market Outlook, by Cancer Type, 2020-2033
    • 6.4.9. South Korea Personalized Cancer Vaccine Market Outlook, by Treatment Setting, 2020-2033
    • 6.4.10. India Personalized Cancer Vaccine Market Outlook, by Vaccine Type, 2020-2033
    • 6.4.11. India Personalized Cancer Vaccine Market Outlook, by Cancer Type, 2020-2033
    • 6.4.12. India Personalized Cancer Vaccine Market Outlook, by Treatment Setting, 2020-2033
    • 6.4.13. Southeast Asia Personalized Cancer Vaccine Market Outlook, by Vaccine Type, 2020-2033
    • 6.4.14. Southeast Asia Personalized Cancer Vaccine Market Outlook, by Cancer Type, 2020-2033
    • 6.4.15. Southeast Asia Personalized Cancer Vaccine Market Outlook, by Treatment Setting, 2020-2033
    • 6.4.16. Rest of SAO Personalized Cancer Vaccine Market Outlook, by Vaccine Type, 2020-2033
    • 6.4.17. Rest of SAO Personalized Cancer Vaccine Market Outlook, by Cancer Type, 2020-2033
    • 6.4.18. Rest of SAO Personalized Cancer Vaccine Market Outlook, by Treatment Setting, 2020-2033
  • 6.5. BPS Analysis/Market Attractiveness Analysis

7. Latin America Personalized Cancer Vaccine Market Outlook, 2020 - 2033

  • 7.1. Latin America Personalized Cancer Vaccine Market Outlook, by Vaccine Type, Value (US$ Bn), 2020-2033
    • 7.1.1. Neoantigen-based
    • 7.1.2. Dendritic Cell
    • 7.1.3. Tumor Cell
    • 7.1.4. Viral Vector-based
  • 7.2. Latin America Personalized Cancer Vaccine Market Outlook, by Cancer Type, Value (US$ Bn), 2020-2033
    • 7.2.1. Melanoma
    • 7.2.2. Lung Cancer
    • 7.2.3. Breast Cancer
    • 7.2.4. Prostate Cancer
    • 7.2.5. Colorectal Cancer
    • 7.2.6. Others
  • 7.3. Latin America Personalized Cancer Vaccine Market Outlook, by Treatment Setting, Value (US$ Bn), 2020-2033
    • 7.3.1. Adjuvant
    • 7.3.2. Metastatic
  • 7.4. Latin America Personalized Cancer Vaccine Market Outlook, by Country, Value (US$ Bn), 2020-2033
    • 7.4.1. Brazil Personalized Cancer Vaccine Market Outlook, by Vaccine Type, 2020-2033
    • 7.4.2. Brazil Personalized Cancer Vaccine Market Outlook, by Cancer Type, 2020-2033
    • 7.4.3. Brazil Personalized Cancer Vaccine Market Outlook, by Treatment Setting, 2020-2033
    • 7.4.4. Mexico Personalized Cancer Vaccine Market Outlook, by Vaccine Type, 2020-2033
    • 7.4.5. Mexico Personalized Cancer Vaccine Market Outlook, by Cancer Type, 2020-2033
    • 7.4.6. Mexico Personalized Cancer Vaccine Market Outlook, by Treatment Setting, 2020-2033
    • 7.4.7. Argentina Personalized Cancer Vaccine Market Outlook, by Vaccine Type, 2020-2033
    • 7.4.8. Argentina Personalized Cancer Vaccine Market Outlook, by Cancer Type, 2020-2033
    • 7.4.9. Argentina Personalized Cancer Vaccine Market Outlook, by Treatment Setting, 2020-2033
    • 7.4.10. Rest of LATAM Personalized Cancer Vaccine Market Outlook, by Vaccine Type, 2020-2033
    • 7.4.11. Rest of LATAM Personalized Cancer Vaccine Market Outlook, by Cancer Type, 2020-2033
    • 7.4.12. Rest of LATAM Personalized Cancer Vaccine Market Outlook, by Treatment Setting, 2020-2033
  • 7.5. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Personalized Cancer Vaccine Market Outlook, 2020 - 2033

  • 8.1. Middle East & Africa Personalized Cancer Vaccine Market Outlook, by Vaccine Type, Value (US$ Bn), 2020-2033
    • 8.1.1. Neoantigen-based
    • 8.1.2. Dendritic Cell
    • 8.1.3. Tumor Cell
    • 8.1.4. Viral Vector-based
  • 8.2. Middle East & Africa Personalized Cancer Vaccine Market Outlook, by Cancer Type, Value (US$ Bn), 2020-2033
    • 8.2.1. Melanoma
    • 8.2.2. Lung Cancer
    • 8.2.3. Breast Cancer
    • 8.2.4. Prostate Cancer
    • 8.2.5. Colorectal Cancer
    • 8.2.6. Others
  • 8.3. Middle East & Africa Personalized Cancer Vaccine Market Outlook, by Treatment Setting, Value (US$ Bn), 2020-2033
    • 8.3.1. Adjuvant
    • 8.3.2. Metastatic
  • 8.4. Middle East & Africa Personalized Cancer Vaccine Market Outlook, by Country, Value (US$ Bn), 2020-2033
    • 8.4.1. GCC Personalized Cancer Vaccine Market Outlook, by Vaccine Type, 2020-2033
    • 8.4.2. GCC Personalized Cancer Vaccine Market Outlook, by Cancer Type, 2020-2033
    • 8.4.3. GCC Personalized Cancer Vaccine Market Outlook, by Treatment Setting, 2020-2033
    • 8.4.4. South Africa Personalized Cancer Vaccine Market Outlook, by Vaccine Type, 2020-2033
    • 8.4.5. South Africa Personalized Cancer Vaccine Market Outlook, by Cancer Type, 2020-2033
    • 8.4.6. South Africa Personalized Cancer Vaccine Market Outlook, by Treatment Setting, 2020-2033
    • 8.4.7. Egypt Personalized Cancer Vaccine Market Outlook, by Vaccine Type, 2020-2033
    • 8.4.8. Egypt Personalized Cancer Vaccine Market Outlook, by Cancer Type, 2020-2033
    • 8.4.9. Egypt Personalized Cancer Vaccine Market Outlook, by Treatment Setting, 2020-2033
    • 8.4.10. Nigeria Personalized Cancer Vaccine Market Outlook, by Vaccine Type, 2020-2033
    • 8.4.11. Nigeria Personalized Cancer Vaccine Market Outlook, by Cancer Type, 2020-2033
    • 8.4.12. Nigeria Personalized Cancer Vaccine Market Outlook, by Treatment Setting, 2020-2033
    • 8.4.13. Rest of Middle East Personalized Cancer Vaccine Market Outlook, by Vaccine Type, 2020-2033
    • 8.4.14. Rest of Middle East Personalized Cancer Vaccine Market Outlook, by Cancer Type, 2020-2033
    • 8.4.15. Rest of Middle East Personalized Cancer Vaccine Market Outlook, by Treatment Setting, 2020-2033
  • 8.5. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

  • 9.1. Company Vs Segment Heatmap
  • 9.2. Company Market Share Analysis, 2025
  • 9.3. Competitive Dashboard
  • 9.4. Company Profiles
    • 9.4.1. Moderna
      • 9.4.1.1. Company Overview
      • 9.4.1.2. Product Portfolio
      • 9.4.1.3. Financial Overview
      • 9.4.1.4. Business Strategies and Developments
    • 9.4.2. Merck & Co.
    • 9.4.3. BioNTech
    • 9.4.4. Genentech (Roche)
    • 9.4.5. Dendreon
    • 9.4.6. CureVac
    • 9.4.7. Transgene
    • 9.4.8. Evaxion Biotech
    • 9.4.9. Nouscom
    • 9.4.10. OSE Immunotherapeutics

10. Appendix

  • 10.1. Research Methodology
  • 10.2. Report Assumptions
  • 10.3. Acronyms and Abbreviations
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!